S16 Ep47: The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH

In today’s episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.

In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it. After discussing the design of the comparison, Dr Shadman then dove into a conversation on the results of the study, in addition to how it will help oncologists and patients alike in the clinic. Finally, Dr Shadman looked to the future of CLL management and underscored what research he would like to see conducted following the comparison and its results.